Identifying Patients With BCG-Unresponsive High-Risk NMIBC Suitable for Treatment With TAR-200
TAR-200 is being studied for carcinoma in situ with or without papillary disease since it addresses diffuse CIS that cannot be surgically removed, though future trials will expand to papillary disease as adjuvant therapy like BCG, with the goal of extending the disease-free period before potentially reintroducing therapy as needed.
EP: 1.An Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC
EP: 3.Overview of the Mechanism of Action of TAR-200 in Patients With BCG-Unresponsive High-Risk NMIBC
EP: 4.Safety Data From the Phase 2B SunRISe-2 Study of TAR-200 in BCG-Unresponsive High-Risk NMIBC
Now Viewing
EP: 5.Identifying Patients With BCG-Unresponsive High-Risk NMIBC Suitable for Treatment With TAR-200
EP: 6.Other Key Trials in the Treatment of BCG-Unresponsive High-Risk NMIBC
EP: 7.Clinical Pearls for Oncologists Treating Patients With BCG-Unresponsive NMIBC
Recent Videos
Related Content
September 16th 2024
Article
The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.
Read More
